Transgenic expression of matrix metalloproteinase-1 inhibits myocardial fibrosis and prevents the transition to heart failure in a pressure overload mouse model

Hypertension Research

Volumn 31, Issue 4, 2008, Pages 725-735

  Foronjy, Robert F ^a   Sun, Jie ^b   Lemaitre, Vincent ^b   d'Armiento, Jeanine M ^b  

^a Columbia University ^*  (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Collagen; Fibrosis; Hypertension; Matrix metalloproteinase

Indexed keywords

INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE MODEL; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE; HEART MUSCLE FIBROSIS; HYPERTENSION; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; AORTA, ABDOMINAL; DISEASE MODELS, ANIMAL; FIBROSIS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEART FAILURE; HYPERTENSION; MALE; MATRIX METALLOPROTEINASE 1; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, TRANSGENIC; MYOCARDIUM; SYSTOLE; TRANSFORMING GROWTH FACTOR BETA; VENTRICULAR REMODELING;

EID: 44649188437     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.725     Document Type: Article

References (50)

1. Izzo JL Jr, Gradman AH: Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure. Med Clin North Am 2004; 88: 1257-1271.
2. Weber KT, Jalil JE, Janicki JS, Pick R: Myocardial collagen remodeling in pressure overload hypertrophy. A case for interstitial heart disease. Am J Hypertens 1989; 2: 931-940.
3. Rossi MA: Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens 1998; 16: 1031-1041.
4. Burlew BS, Weber KT: Cardiac fibrosis as a cause of diastolic dysfunction. Herz 2002; 27: 92-98.
5. Katz AM: The cardiomyopathy of overload: an unnatural growth response. Eur Heart J 1995; 16 (Suppl O): 110-114.
6. Martos R, Baugh J, Ledwidge M, et al: Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007; 115: 888-895.
7. Caulfield JB, Borg TK: The collagen network of the heart. Lab Invest 1979; 40: 364-372.
8. Spotnitz HM: Macro design, structure, mechanics of the left ventricle. J Thorac Cardiovasc Surg 2000; 119: 1053-1077.
9. Kuhn K: The classical collagens: types I, II and III, in Mayne R, Burgeson RE (eds): Structure and Function of Collagen Types. London, Academic Press, 1987, pp 1-42.
10. Nagase H: Activation mechanisms of matrix metalloproteinases. Biol Chem 1997; 378: 151-160.
11. Jeffrey JJ: Interstitial Collagenase. London, Academic Press, 1998, pp 15-42.
12. Sakata Y, Yamamoto K, Mano T, et al: Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of angiotensin-converting enzyme inhibitor. Circulation 2004; 109: 2143-2149.
13. Janicki JS, Brower GL, Gardner JD, Chancey AL, Stewart JA Jr: The dynamic interaction between matrix metalloproteinase activity and adverse myocardial remodeling. Heart Fail Rev 2004; 9: 33-42.
14. Kassiri Z, Oudit GY, Sanchez O, et al: Combination of tumor necrosis factor-alpha ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice. Circ Res 2005; 97: 380-390.
15. Kim RE, Dalal SS, Young E, Legato MJ, Weisfeldt ML, D'Armiento J: Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. J Clin Invest 2000; 106: 857-866.
16. Nagatomo Y, Carabello BA, Coker ML, et al: Differential effects of pressure or volume overload on myocardial MMP levels and inhibitory control. Am J Physiol Heart Circ Physiol 2000; 278: H151-H161.
17. Kozak M: Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell 1986; 44: 283-292.
18. Chada K, Magram J, Raphael K, Radice G, Lacy E, Costantini F: Specific expression of a foreign beta-globin gene in erythroid cells of transgenic mice. Nature 1985; 314: 377-380.
19. Rockman HA, Ross RS, Harris AN, et al: Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc Natl Acad Sci USA 1991; 88: 8277-8281.
20. Woessner JF Jr: The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 1961; 93: 440-447.
21. Pardo Mindan FJ, Panizo A: Alterations in the extracellular matrix of the myocardium in essential hypertension. Eur Heart J 1993; 14 (Suppl J): 12-14.
22. Tanaka M, Fujiwara H, Onodera. T, Wu DJ, Hamashima. Y, Kawai C: Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J 1986; 55: 575-581.
23. Brilla CG, Funck RC, Rupp H: Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102: 1388-1393.
24. Gonzalez A, Lopez B, Querejeta R, Diez J: Regulation of myocardial fibrillar collagen by angiotensin II. A role in hypertensive heart disease? J Mol Cell Cardiol 2002; 34: 1585-1593.
25. Lopez B, Querejeta R, Varo N, et al: Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001; 104: 286-291.
26. Shirwany A, Weber KT: Extracellular matrix remodeling in hypertensive heart disease. J Am Coll Cardiol 2006; 48: 97-98.
27. Laviades C, Varo N, Fernandez J, et al: Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998; 98: 535-540.
28. Marin F, Roldan V, Climent V, Garcia A, Marco P, Lip GY: Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1? Stroke 2003; 34: 1181-1186.
29. Lindsay MM, Maxwell P, Dunn FG: TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 2002; 40: 136-141.
30. Heymans S, Schroen B, Vermeersch P, et al: Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-over-loaded human heart. Circulation 2005; 112: 1136-1144.
31. Kawano H, Do YS, Kawano Y, et al: Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 2000; 101: 1130-1137.
32. Dostal DE: Regulation of cardiac collagen: angiotensin and cross-talk with local growth factors. Hypertension 2001; 37: 841-844.
33. Chua CC, Chua BH, Zhao ZY, Krebs C, Diglio C, Perrin E: Effect of growth factors on collagen metabolism in cultured human heart fibroblasts. Connect Tissue Res 1991; 26: 271-281.
34. Edwards DR, Murphy G, Reynolds JJ, et al: Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 1987; 6: 1899-1904.
35. Hall MC, Young DA, Waters JG, et al: The comparative role of activator protein 1 and Smad factors in the regulation of Timp-1 and MMP-1 gene expression by transforming growth factor-beta 1. J Biol Chem 2003; 278: 10304-10313.
36. Robinson TF, Cohen-Gould L, Factor SM: Skeletal framework of mammalian heart muscle. Arrangement of inter-and pericellular connective tissue structures. Lab Invest 1983; 49: 482-498.
37. Robinson TF, Factor SM, Capasso JM, Wittenberg BA, Blumenfeld OO, Seifter S: Morphology, composition, and function of struts between cardiac inyocytes of rat and hamster. Cell Tissue Res 1987; 249: 247-255.
38. Baicu CF, Stroud JD, Livesay VA, et al: Changes in extracellular collagen matrix alter myocardial systolic performance. Am J Physiol Heart Circ Physiol 2003; 284: H122-H132.
39. Matsubara LS, Matsubara BB, Okoshi MP, Cicogna AC, Janicki JS: Alterations in myocardial collagen content affect rat papillary muscle function. Am J Physiol Heart Circ Physiol 2000; 279: H1534-H1539.
40. Li W, Tanaka K, Chiba Y, et al: Role of MMPs and plasminogen activators in angiogenesis after transmyocardial laser revascularization in dogs. Am J Physiol Heart Circ Physiol 2003; 284: H23-H30.
41. Siwik DA, Pagano PJ, Colucci WS: Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol 2001; 280: C53-C60.
42. 2- and ICAM-1 levels in a rat model with aortic remodeling induced by pressure overload. Am J Physiol Heart Circ Physiol 2001; 281: H655-H660.
43. Altieri P, Brunelli C, Garibaldi S, et al: Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur J Clin Invest 2003; 33: 648-1656.
44. Squire IB, Evans J, Ng LL, Loftus IM, Thompson MM: Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiograpbic and neurohumoral parameters of left ventricular dysfunction. J Card Fail 2004; 10: 328-333.
45. Hayasbidani S, Tsutsui H, Ikeuchi M, et al: Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol 2003; 285: H1229-H1235.
46. Matsumura S, Iwanaga S, Mochizuki S, Okamoto H, Ogawa S, Okada Y: Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest 2005; 115: 599-609.
47. Creetners EE, Davis JN, Parkhurst AM, et al: Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol 2003; 284: H364-H371.
48. Heymans S, Lupu F, Terclavers S, et al: Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol 2005; 166: 15-25.
49. Lee RT: Matrix metalloproteinase inhibition and the prevention of heart failure. Trends Cardiovasc Med 2001; 11: 202-205.
50. Lindsey M, Lee RT: MMP inhibition as a potential therapeutic strategy for CHF. Drug News Perspect 2000; 13: 350-354.